medigraphic.com
Revista Médica Sinergia

2020, Número 12

<< Anterior Siguiente >>

Revista Médica Sinergia 2020; 5 (12)


Enfermedad inflamatoria intestinal durante el embarazo: consideraciones terapéuticas

Chaves SM, Garnier FJC, Pérez MJD

Idioma: Español
Referencias bibliográficas: 28
Paginas: 1-14
Archivo PDF: 190.67 Kb.


RESUMEN

La enfermedad inflamatoria intestinal es una condición crónica inflamatoria, compleja y multifactorial, que ha venido siendo más incidente y prevalente en las últimas décadas. Con los años, se han creado diversos medicamentos para el manejo de la enfermedad, tanto en periodos de exacerbación como de mantenimiento, con el objetivo primordial de mantenerla en remisión. Debido a que las mujeres en edad reproductiva no son excluidas del diagnóstico, en caso de un embarazo, es necesario definir la terapia más adecuada, considerando los beneficios maternos del tratamiento y el riesgo fetal que podría tener la terapia a utilizar.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Parvez H, Usman N, Ahmed M, Hashmi M. The impact of inflammatory bowel disease on pregnancy and the fetus: a literatura review. Cureus. 2019;11(9): e5648. https://doi.org/10.7759/cureus.5648

  2. Lima-Karagannis A, Zelinkova-Detkova Z, Janneke van der Woude C. The effects of active IBD during pregnancy in the era of novel IBD therapies. Am J Gastroenerol. 2016;111(9):1305-1312. https://doi.org/10.1038/ajg.2016.254

  3. Van der Giessen J, Huang V, van der Woude J, Fuhler G. Modulatory effects of pregnancy on inflammatory bowel disease. Clin Transl Gastro. 2019;10:e-00009. https://doi.org/10.14309/ctg.0000000000000009

  4. Mahadevan U, Robinson C, Bernasko N, Boland B, Chambers C, Dubinsky M, et al. Inflammatory bowel disease in pregnancy clinical care pathway: a report from the American Gastroenterological Association IBD parenthood project working group. Gastroenterology. 2019;156:1508-1524. https://doi.org/10.1053/j.gastro.2018.12.022

  5. Koslowsky B, Grisaru-Granovsky S, Livovsky DM, Milgrom Y, Goldin E. Pregnanacy-Onset inflammatory bowel disease: a subtle diagnosis. Inflamm Bowel Dis. 2018; 24(8):1826-1832. https://doi.org/10.1093/ibd/izy081

  6. Singh S, Picardo S, Seow C. Management of Inflammatory Bowel Diseases in Special Populations: Obese, Old, or Obstetric. Clinical Gastroenterol and Hepatol. 2020; 18(6): 1367-1380. https://doi.org/10.1016/j.cgh.2019.11.009

  7. McConnell R, Mahadevan U. Pregnancy and the patient with inflammatory bowel disease: fertility, treatment, delivery and complications. Gastroenterol Clin N Am. 2016;45:285-301. https://doi.org/10.1016/j.gtc.2016.02.006

  8. Jameson JL, Fauci AS, Kasper DL, Hauser SL, Longo DL, Loscalzo J. Harrison's Principles of Internal Medicine. 20 ed. New York: McGraw-Hill; 2018.

  9. Feldman M, Friedman LS, Brandt LJ. Sleisenger and Fordtran's Gastrointestinal and Liver Disease. 10 ed. Philadelphia: Elsevier; 2016.

  10. Quingdong Guan. A Comprehensive Review and Update on the Pathogenesis of Inflammatory Bowel Disease. J Immunol Res. 2019 (2019). https://doi.org/10.1155/2019/7247238

  11. Peppercorn MA, Cheifetz AS. Definitions, epidemiology, and risk factors for inflammatory bowel disease in adults. Uptodate. [Internet] [Consultado 8 de abril del 2020] 2019; 05-01. Disponible en: https://www.uptodate.com/contents/definitions-epidemiology-and-risk-factors-for-inflammatory-boweldisease- in-adults

  12. Van der Giessen J, Binyamin D, Belogolovski A, Frishman S, Tenenbaum-Gavish K, Hadar E, et al. Modulation of cytokine patterns and microbiome during pregnancy in IBD. Gut. 2020;69:473-486. https://doi.org/10.1136/gutjnl-2019-318263

  13. Fuhler G. The immune system and microbiome in pregnancy. Best Practice & Research Clinical Gastroenterology. 2020;44-45 (2020):101671. https://doi.org/10.1016/j.bpg.2020.101671

  14. Rubin, DT, Ananthakrishnan AN, Siegel CA, Sauer BG, Long MD. ACG Clinical Guideline: Ulcerative Colitis in Adults. Am J Gastroenterol. 2019; 114(3):384-413. https://doi.org/10.14309/ajg.0000000000000152

  15. Lichtenstein GR, Loft us Jr EV, Isaacs KL, Regueiro MD, Gerson LB, Sands BE. ACG Clinical Guideline: Management of Crohn's Disease in Adults. Am J Gastroenterol. 2018; 113(4):481-517; https://doi.org/10.1038/ajg.2018.27

  16. Nguyen G, Seow C, Maxwell C, Huang V, Leung Y, Jones J, Leontiadis, et al. The Toronto consensus statements for the management of inflammatory bowel disease in pregnancy. Gastroenterology. 2016;150:734-757. https://doi.org/10.1053/j.gastro.2015.12.003

  17. Ludvigsson JF, Lebwohl B, Ekbom A, Pokala-Kiran R, Green PH, Hoijer J, Stephansson O. Outcomes of pregnancies for women undergoing endoscopy while they were pregnant: a nationwide cohort study. Gastroenterology. 2017;152:554-563. https://doi.org/10.1053/j.gastro.2016.10.016

  18. Biancone L, Annese V, Ardizzone S, Armuzzi A, Calabrese E, Caprioli F, et al. Safety of treatments for inflammatory bowel disease: clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). Digest Liver Dis. 2017;49:338-358. https://doi.org/10.1016/j.dld.2017.01.141

  19. Panayiotis G, Thomas A, Lodhia N. Medical therapy for inflammatory bowel disease. Sur Clin N Am. 2015;95:1159-1182. https://doi.org/10.1016/j.suc.2015.08.004

  20. Cheifetz A, Cullen G. Sulfasalazine and 5-aminosalicylates in the treatment of inflammatory bowel disease. UptoDate [Internet] [Consultado 08 abril 2020] 2020. Disponible en: https://www.uptodate.com/contents/sulfasalazine-and-5-aminosalicylates-in-the-treatment-ofinflammatory- bowel-disease

  21. American college of obstetricians and gynecologists. ACOG Committee Opinion No. 776: Immune modulating therapies in pregnancy and lactation. Obstet Gynecol. 2019;133(4):e287-e295. https://doi.org/10.1097/AOG.0000000000003176

  22. Dingsdag SA, Hunter N. Metronidazole: an update on metabolism, structure-cytotoxicity and resistance mechanisms. J Antimicrob Chemother 2018; 73: 265-279. https://doi.org/10.1093/jac/dkx351

  23. Mahadevan U, McConnell RA, Chambers CD. Drug safety and risk of adverse outcomes for pregnant patients with inflammatory bowel disease. Gastroenterology. 2017;152:451-462. https://doi.org/10.1053/j.gastro.2016.10.013

  24. Acar S, Keskin-Arslan E, Erol-Coskun H, Kaya-Temiz T, Kaplan YC. Pregnancy outcomes following quinolone and fluoroquinolone exposure during pregnancy: a systematic review and meta-analysis. Reproductive Toxicology. 2019;85:65-74. https://doi.org/10.1016/j.reprotox.2019.02.002

  25. Engel T, Yung DE, Ma C, Pariente B, Wlls P, Eliakim R, et al. Effectiveness and safety of ustekinumab for Crohn's disease; systematic review and pooled análisis of real-world evidence. Digest Liver Dis. 2019;51:1232-1240. https://doi.org/10.1016/j.dld.2019.05.002

  26. Matro R, Martin CF, Wolf D, Shah S, Mahadevan U. Exposure concentrations of infants breastfed by women receiving biologic therapies for inflammatory bowel diseases and effects of breastfeeding on infections and development. Gastroenterology. 2018;155:696-704. https://doi.org/10.1053/j.gastro.2018.05.040

  27. Pérez-Jeldres T, Tyler CJ, Boyer JD, Karuppuchamy T, Yarur A, Giles DA. Targeting cytokine signaling and lymphocyte traffic via small molecules in inflammatory bowel disease: JAK inhibitors and S1PR agonists. Front Pharmacol. 2019;10(212):1-15. https://doi.org/10.3389/fphar.2019.00212

  28. Singh S, Allegretti JR. AGA technical review on the management of moderate to severe ulcerative colitis. Gastroenterology. 2020;158:1465-1496. https://doi.org/10.1053/j.gastro.2020.01.007




2020     |     www.medigraphic.com